Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q0IIM8
UPID:
TBC8B_HUMAN
Alternative names:
-
Alternative UPACC:
Q0IIM8; B9A6K5; B9A6K6; Q5JRB7; Q6ZVX5; Q9NXE3
Background:
TBC1 domain family member 8B plays a crucial role in vesicular recycling, acting as a RAB11B GTPase-activating protein. This protein's involvement in cellular trafficking underscores its importance in maintaining cellular function and homeostasis.
Therapeutic significance:
Nephrotic syndrome 20, a severe renal disease leading to end-stage renal failure, is linked to variants affecting TBC1 domain family member 8B. Understanding this protein's role could pave the way for novel therapeutic strategies targeting the underlying genetic causes of this condition.